Frazier Life Sciences Management, L.P. Portfolio Holdings

Frazier Life Sciences Management, L.P.

  • $1.9 Billion
  • Q2 2025

Frazier Life Sciences Management, L.P. has filed its 13F form on August 14, 2025 for Q2 2025 where it was disclosed a total value porftolio of $1.9 Billion distributed in 49 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Mirum Pharmaceuticals, Inc. with a value of $346M, Verona Pharma PLC with a value of $320M, Bridge Bio Pharma, Inc. with a value of $164M, Arcutis Biotherapeutics, Inc. with a value of $138M, and Phathom Pharmaceuticals, Inc. with a value of $120M.

Examining the 13F form we can see an increase of $307M in the current position value, from $1.59B to 1.9B.

Frazier Life Sciences Management, L.P. is based out at Menlo Park, CA

Below you can find more details about Frazier Life Sciences Management, L.P. portfolio as well as his latest detailed transactions.

Portfolio value $1.9 Billion
Healthcare: $1.9 Billion

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History
$2.38B
$346 Million 18.24% of portfolio
6,795,121
Q1 2025 Added 3.42%
$6.41B
$320 Million 16.88% of portfolio
3,383,950
Q2 2025 Reduced 2.14%
$7.28B
$164 Million 8.65% of portfolio
3,800,457
Q4 2024 Added 1.06%
$887M
$138 Million 7.3% of portfolio
9,874,511
Q2 2025 Added 12.4%
$407M
$120 Million 6.31% of portfolio
12,466,489
Q2 2025 Added 23.32%
$3.69B
$94.6 Million 4.99% of portfolio
688,460
Q1 2025 Reduced 12.68%
$1.37B
$56.6 Million 2.99% of portfolio
1,397,527
Q1 2025 Reduced 11.97%
$428M
$56.1 Million 2.96% of portfolio
10,259,409
Q1 2025 Reduced 3.8%
$301M
$55.3 Million 2.92% of portfolio
4,887,867
Q4 2024 Added 32.54%
$3.36B
$45.7 Million 2.41% of portfolio
1,308,138
Q2 2025 Added 273.75%
$1.94B
$42.6 Million 2.24% of portfolio
1,279,754
Q2 2025 Added 19.62%
$3.09B
$36.7 Million 1.94% of portfolio
997,455
Q3 2023 Added 16.73%
$1.97B
$35.8 Million 1.89% of portfolio
983,715
Q2 2025 Added 49.34%
$203M
$31.9 Million 1.68% of portfolio
5,100,000
Q2 2025 New
$191M
$28.9 Million 1.52% of portfolio
22,729,436
Q2 2025 Added 0.68%
$4.49B
$28.6 Million 1.51% of portfolio
1,000,647
Q2 2025 Added 66.46%
$207M
$25.6 Million 1.35% of portfolio
9,440,112
Q2 2025 Added 20.72%
$10.9B
$23 Million 1.21% of portfolio
133,333
Q3 2024 New
$359M
$22.4 Million 1.18% of portfolio
2,435,550
Q2 2025 New
$69.5M
$21.1 Million 1.11% of portfolio
10,617,062
Q2 2024 Added 8.54%
$2.23B
$19.6 Million 1.03% of portfolio
366,784
Q2 2025 New
$3.23B
$18.3 Million 0.97% of portfolio
554,731
Q2 2025 New
$2.41B
$17.8 Million 0.94% of portfolio
625,000
Q2 2025 Added 19.05%
$1.78B
$15.4 Million 0.81% of portfolio
474,405
Q2 2025 Reduced 12.05%
$1.12B
$14.8 Million 0.78% of portfolio
1,002,092
Q2 2025 New
$602M
$14.3 Million 0.76% of portfolio
1,505,984
Q2 2025 Added 4.34%
$760M
$12.5 Million 0.66% of portfolio
1,734,601
Q2 2025 Added 85.21%
$1.4B
$12.1 Million 0.64% of portfolio
384,782
Q2 2025 Added 27.76%
$377M
$10.8 Million 0.57% of portfolio
1,065,334
Q2 2025 Reduced 24.45%
$195M
$10.5 Million 0.56% of portfolio
4,623,324
Q1 2024 Added 23.39%
$650M
$8.27 Million 0.44% of portfolio
1,458,333
Q2 2025 New
$278M
$6.58 Million 0.35% of portfolio
1,953,547
Q4 2024 Added 3.22%
$201M
$5.63 Million 0.3% of portfolio
970,130
Q2 2025 Reduced 15.54%
$148M
$4.37 Million 0.23% of portfolio
3,868,750
Q1 2025 Added 34.91%
$90.3M
$3.84 Million 0.2% of portfolio
3,175,665
Q4 2024 Added 5.48%
$8.39M
$2.22 Million 0.12% of portfolio
5,993,579
Q3 2024 Added 102.58%
Cg Oncology Inc
-
$0 0.0% of portfolio
-
Q1 2024 New
Crescent Biopharma Inc.
-
$0 0.0% of portfolio
-
Q2 2025 New
Adverum Biotechnologies Inc
-
$0 0.0% of portfolio
-
Q2 2024 New
Disc Medicine Inc
-
$0 0.0% of portfolio
-
Q2 2025 Reduced 5.7%
Lexeo Therapeutics Inc
-
$0 0.0% of portfolio
-
Q2 2025 Added 363.07%
Oruka Therapeutics Inc
-
$0 0.0% of portfolio
-
Q4 2024 Added 22.21%
-
$0 0.0% of portfolio
-
Q4 2022 New
-
$0 0.0% of portfolio
-
Q2 2025 Added 3.04%
Jade Biosciences Inc
-
$0 0.0% of portfolio
-
Q2 2025 New
Mbx Biosciences Inc
-
$0 0.0% of portfolio
-
Q3 2024 New
Maze Therapeutics Inc
-
$0 0.0% of portfolio
-
Q2 2025 Added 10.61%
Palvella Therapeutics Inc Ne
-
$0 0.0% of portfolio
-
Q2 2025 Added 4.69%

Summary

  • Portfolio
  • No. of Stocks 49
  • Current Value $1.9 Billion
  • Prior Value $1.59 Billion
  • Filing
  • Period Q2 2025
  • Filing Date August 14, 2025
  • Form Type 13F-HR
  • Activity in Q2 2025
  • New Purchases 8 stocks
  • Additional Purchases 16 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 5 stocks
Track This Portfolio

Track Frazier Life Sciences Management, L.P. Portfolio

Follow Frazier Life Sciences Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Frazier Life Sciences Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Frazier Life Sciences Management, L.P. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email